These data showed that Ctr1 deficiency inhibited α-syn-mediated pathologies, suggesting that Ctr1 is a key modulator to α-syn neurotoxicity and it may merit clinical consideration of modifying therapies in PD and other synucleinopathies. This evidence concerns the gene SLC31A1 and Parkinson disease.